Diet for Hypoglycemia - Diet For Hypoglycemia News

Diet For Hypoglycemia News

Research may assist to find possible avenue for anti-aging drugs Thursday, August 19, 2010 @ 1:19AMA team of University of Michigan scientists has found that suppressing a newly discovered gene lengthens the lifespan of roundworms. Scientists who study aging have long known that significantly restricting food intake makes animals live longer. But the goal is to find less drastic ways to achieve the same effect in humans someday. The U-M results offer promising early evidence that scientists ...
Data From Meta-Analysis Show Victoza(R) Achieved Improved Blood Sugar Control in African-Americans With Type 2 Diabetes Wednesday, August 4, 2010 @ 7:18AMORLANDO, FL--(Marketwire - August 4, 2010) - Novo Nordisk ( NYSE : NVO ) presented results today demonstrating that once-daily Victoza ® (liraglutide [rDNA] injection) achieved significantly greater improvements in blood sugar control compared to placebo among African-American patients with type 2 diabetes. The meta-analysis of phase 3 data from the Liraglutide Effect and Action in Diabetes ...
Data From Meta-Analysis Show Victoza(R) Achieved Improved Blood Sugar Control in African-Americans With Type 2 Diabetes Wednesday, August 4, 2010 @ 7:00AMORLANDO, FL--(Marketwire - 08/04/10) - Novo Nordisk (NYSE: NVO - News ) presented results today demonstrating that once-daily Victoza (liraglutide [rDNA ] injection) achieved significantly greater improvements in blood sugar control compared to placebo among African-American patients with type 2 diabetes. The meta-analysis of phase 3 data from the Liraglutide Effect and Action in Diabetes (LEAD ...
Diabetes care: Implanted glucose sensor works for more than a year in animal studies Wednesday, July 28, 2010 @ 2:56PMBioengineers have developed an implantable glucose sensor and wireless telemetry system that continuously monitors tissue glucose and transmits the information to an external receiver. A new article describes the use of this glucose-sensing device as an implant in animals for over one year. After human clinical trials and FDA approval, the device may be useful to people with diabetes as an ...
Implanted glucose sensor works for more than 1 year Wednesday, July 28, 2010 @ 1:16PM( University of California - San Diego ) Bioengineers at the University of California, San Diego and GlySens Incorporated have developed an implantable glucose sensor and wireless telemetry system that continuously monitors tissue glucose and transmits the information to an external receiver. The paper, published in the July 28, 2010 issue of the journal Science Translational Medicine, describes ...
Implanted glucose sensor works for more than one year, could aid diabetes patients Wednesday, July 28, 2010 @ 1:11PMBioengineers developed an implantable glucose sensor and wireless telemetry system that continuously monitors tissue glucose and transmits the information to an external receiver. The paper, to be published in the July 28, 2010 issue of the journal Science Translational Medicine, describes the use of this glucose-sensing device as an implant in animals for over one year. After human clinical ...
Pomeranian puppies stolen in plain daylight Tuesday, July 27, 2010 @ 8:24PMPolice are looking for two men who stole three pedigreed Pomeranian puppies from a North Valley family, and brought a gun along to seal the deal.
Patterson Irrigator - blood sugar monitor diabetic supplies test meter Monday, July 26, 2010 @ 8:43AMBlood Sugar Monitor - Diabetic Supplies Test Meter - Type 2 diabetes is a "silent" disease. Although you can feel thirsty, tired, hungry, or have frequent urination or blurry vision when blood sugar creeps into the danger zone, often there are no symptoms at all.
LiveWell: Hypoglycemia Monday, July 26, 2010 @ 12:00AMWhen the body's supply of glucose in the bloodstream runs low, so does the ability to perform daily tasks successfully. Individuals may suffer for weeks without proper diagnosis. Symptoms of a hypoglycemic reaction also can arise suddenly and seemingly out of nowhere, often as a result of being more physically active than usual.
HIGHER GROUND: Getting a new look from the Old Book Sunday, July 25, 2010 @ 10:05AMBest-selling author, Charlie Shedd, who had struggled with obesity for years, was one of the first to write on Bible based weight loss. In his book, “The Fat is in Your Head” he says he dropped to his knees one day and prayed, “Lord I’ve tried for years to whip this problem of obesity.
Lilly Reports Strong Second-Quarter 2010 Results Thursday, July 22, 2010 @ 5:30AM-
Study: Insulin Pump Better Than Injections Wednesday, July 21, 2010 @ 6:31PMEncouraging research raises new hopes that a long awaited "artificial pancreas" to treat patients with type 1 diabetes could be available in the U.S. within the next few years, experts say.
Blood sugar control during pregnancy is a must Saturday, July 17, 2010 @ 12:01AM17 July 2010 DUBAI - While most of the pregnancies are uncomplicated, reach to term, and deliver healthy newborn uneventfully, a few may be complicated.
Research Roundup Thursday, July 15, 2010 @ 11:20PMFor the complete stories on this research, click on the title of each summary.
Concerned about Avandia? Here are other options Thursday, July 15, 2010 @ 9:52AMEdward Darden started taking the diabetes drug Avandia in 2006 to help control his blood sugar and was doing just fine, he said. But he became concerned when he saw warnings linking the drug to a 43 percent increased risk of heart attack, following the 2007 release of a study in the "New England Journal of Medicine."
Barbara Quinn: Coping with diabetes 24/7 Wednesday, June 30, 2010 @ 3:40AMWe were having a conversation in the lobby of the hospital where I work. And I knew right away that retired businessman Bob Dehlendorf was passionate about this topic. "Do you know what type 1 diabetes is?" he began. "Do you know what it's like to have type 1 diabetes? ...
Medtronic's 24-Hour Diabetes Monitors Beat Standard Therapy, Study Shows Tuesday, June 29, 2010 @ 8:09AMMedtronic Inc .’s device enabling diabetics to continuously monitor their blood-sugar levels was almost three times as effective as standard therapy at controlling their glucose in a study. Children also benefited.
Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease ... Tuesday, June 29, 2010 @ 6:00AMIsis Pharmaceuticals, Inc. announced today that data from seven programs in Isis' broad metabolic disease franchise were presented at the American Diabetes Association's 70th Scientific Sessions in Orlando. Â These presentations included two oral talks highlighting data from Isis' Phase 2 study of ISIS 113715 in patients with type 2 diabetes and Isis' Phase 1 study of ISIS-GCGRRx.
AFREZZA provides long-term glucose control in Type 2 diabetics: Study Tuesday, June 29, 2010 @ 3:09AMAFREZZA (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, investigational ultra rapid acting mealtime insulin, as part of a diabetes treatment regimen, provides long-term glucose control comparable to usual insulin therapy but with a significantly reduced incidence of hypoglycemia and less weight gain in patients with Type 2 diabetes, according to a two-year study presented ...
New Data Demonstrates Victoza(R) (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control ... Monday, June 28, 2010 @ 7:08AMORLANDO, FL--(Marketwire - June 28, 2010) - Poster 16LB -- Late-breaking Novo Nordisk ( NYSE : NVO ) extension data presented today at the 70 th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily Victoza ® in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose (FPG) than ...
New Data Demonstrates Victoza® (liraglutide [rDNA ] injection) Provided Superior and Sustained Blood Sugar Control and ... Monday, June 28, 2010 @ 7:00AMPoster 16LB -- Late-breaking Novo Nordisk extension data presented today at the 70th Annual Scientific Sessions of the American Diabetes Association showed that once-daily VictozaÂ® in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose than JanuviaÂ® plus metformin at 52 weeks.
New Clinical Study Shows Patients With Type 2 Diabetes May Be Able to Tolerate Higher Doses of Metformin Using GLUMETZA Monday, June 28, 2010 @ 7:00AMDepomed, Inc. and Santarus, Inc. today announced new data suggesting that patients previously intolerant of metformin may be able to tolerate higher doses of metformin when treated with GLUMETZAÂ® . Â The findings [abstract #0729-P ] will be presented at the 70th Scientific Sessions of the American Diabetes Association in Orlando.
New Data Demonstrates Victoza(R) (liraglutide [rDNA ] injection) Provided Superior and Sustained Blood Sugar Control ... Monday, June 28, 2010 @ 7:00AMORLANDO, FL--(Marketwire - 06/28/10) - Poster 16LB -- Late-breaking Novo Nordisk (NYSE: NVO - News ) extension data presented today at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily Victoza in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose (FPG) than Januvia ...
New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and ... Saturday, June 26, 2010 @ 1:30PMORLANDO, Fla., June 26 /PRNewswire-FirstCall/ -- Poster 16LB -- Late-breaking Novo Nordisk (NVO) extension data presented today at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily Victoza® in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose (FPG) than Januvia® ...
Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in ... Saturday, June 26, 2010 @ 1:29PMORLANDO, Fla., June 26 /PRNewswire/ -- Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c (HbA1c),(1-4) fasting plasma glucose (FPG)(1-4) and postprandial glucose (PPG).(1,2) Boehringer Ingelheim Pharmaceuticals, Inc.
Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic ... Saturday, June 26, 2010 @ 1:29PMORLANDO, Fla., June 26, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 Saturday, June 26, 2010 @ 10:43AMORLANDO, Fla., June 26, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc.
Ipsens partner Roche confirms the promising efficacy profile of Taspoglutide Saturday, June 26, 2010 @ 9:14AMTwo additional Phase III studies showed that taspoglutide, when used alone or added to metformin (the most common first-line treatment for type 2 diabetes), significantly reduced HbA1c and body weight with low risk of hypoglycemia.
BUSINESS WIRE: Ipsen's partner Roche confirms the promising efficacy profile of Taspoglutide Saturday, June 26, 2010 @ 9:08AMMITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.
New data demonstrates Victoza(R) (liraglutide [rDNA] injection) provided superior and sustained blood sugar control ... Saturday, June 26, 2010 @ 9:07AMORLANDO, FL--(Marketwire - June 26, 2010) - Poster 16LB -- Late-breaking Novo Nordisk ( NYSE : NVO ) extension data presented today at the 70 th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily Victoza ® in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose (FPG) than ...
Health Calendar Thursday, June 24, 2010 @ 4:28AMFitness
Health Calendar Thursday, June 24, 2010 @ 4:12AMAdventist Paulson Rehab Network , 619 Plainfield Road, Willowbrook, offers different fitness and exercise regimens including pre and post natal exercise, pool class, advanced circuit training program, keep it moving small group exercise class, arthritis foundation aquatic program, aquatic exercise classes and therapeutic massage.
Dapagliflozin as monotherapy demonstrates improved glycemic control in treatment-naïve adults with type 2 diabetes Thursday, June 24, 2010 @ 2:42AMFindings from a 24-week phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in the primary endpoint of glycosylated haemoglobin levels (HbA1c) in treatment-naïve adult patients with newly diagnosed ...
Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment Wednesday, June 23, 2010 @ 4:37AMFindings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in the primary endpoint of glycosylated hemoglobin levels (HbA1c) in treatment-naïve adult patients with newly diagnosed ...
Dapagliflozin as Monotherapy Demonstrated Improved Glycemic Control in Treatment-Naïve Adults with Type 2 Diabetes Tuesday, June 22, 2010 @ 9:00AMPRINCETON, N.J. & WILMINGTON, Del.----Findings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in the primary endpoint of glycosylated hemoglobin levels in treatment-naïve adult ...
BYDUREON efficacy & tolerability profile extended to monotherapy treatment: DURATION-4 study Friday, June 18, 2010 @ 7:42AMAmylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of BYDUREON (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, as compared to other type 2 diabetes medications.
Amylin Pharmaceuticals to Present New Data and Insights From the Company's Diabetes Programs at ADA 2010 Thursday, June 17, 2010 @ 6:15PMSAN DIEGO, June 17, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals to Present New Data and Insights From the Company's Diabetes Programs at ADA 2010 Thursday, June 17, 2010 @ 3:15PMAmylin Pharmaceuticals, Inc. today announced that the Company will present data for its FDA-approved diabetes drugs, BYETTAÂ® injection and SYMLINÂ® injection, and its investigational diabetes drug candidate BYDUREONâ¢ at the American Diabetes Association's 70th Annual Scientific Sessions being held in Orlando, FL from June 25 to June 29.
DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment Tuesday, June 15, 2010 @ 7:15AMSAN DIEGO & INDIANAPOLIS & WALTHAM, Mass.----Amylin Pharmaceuticals, Inc. , Eli Lilly and Company and Alkermes, Inc. today announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of BYDUREON™ , an investigational type 2 diabetes therapy, as compared to other type 2 diabetes medications.
DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment Tuesday, June 15, 2010 @ 7:03AMread more
DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment Tuesday, June 15, 2010 @ 7:00AMAmylin Pharmaceuticals, Inc. , Eli Lilly and Company and Alkermes, Inc. today announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of BYDUREONâ¢ , an investigational type 2 diabetes therapy, as compared to other type 2 diabetes medications.
70 million Indians to suffer from diabetes: Doc Monday, May 24, 2010 @ 9:54AMKolkata, May 24: India has the dubious distinction of being the Diabetes Capital of the World with 51 million (7.1pc ) of its adult population suffering from diabetes though recently China has attained this distinction.
Robotic Pancreas: One Man's Quest to Put Diabetics on Autopilot Sunday, May 16, 2010 @ 11:35PMWhen Jeff Brewer, co-founder of two early internet juggernauts, learned his son had diabetes, he became advocate-in-chief for bringing to market a fully automated, self-regulating artificial organ that would release just the right amount of insulin at just the right time.
Novo Nordisk Partners With International Scientific Community For Victoza(R) Cardiovascular Outcomes Trial Wednesday, May 12, 2010 @ 7:50AMNovo Nordisk (NVO) announced details of the company's cardiovascular outcomes trial for Victoza® (liraglutide [rDNA origin] injection), which is set to start in the autumn of 2010. The trial named LEADER™ (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) aims to assess and confirm the cardiovascular safety of the company's new once-daily human GLP-1 analog ...
Report: Griffey fell asleep in clubhouse during game Monday, May 10, 2010 @ 4:40PMFor those wondering how much longer Ken Griffey Jr.'s run will last with the Seattle Mariners, Tacoma News Tribune beat writer Larry LaRue has an answer.
BYDUREON™ FDA Review Timeline Set With PDUFA Action Date Of October 22, 2010 Sunday, May 9, 2010 @ 5:27AMAmylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) announced that the U.S. Food and Drug Administration (FDA) has classified the BYDUREON™ (exenatide for extended-release injectable suspension) complete response as a Class 2 resubmission and assigned a new Prescription Drug User Fee Act (PDUFA) action date of October 22, 2010...
The YOU Docs: Real health care reform must start at home Friday, May 7, 2010 @ 12:49AMEveryone is worked up over health care reform. But amid the shouting, are you hearing much about health?
BYDUREON FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 Thursday, May 6, 2010 @ 7:15AMSAN DIEGO, INDIANAPOLIS, & WALTHAM, Mass.----Amylin Pharmaceuticals, Inc. , Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration has classified the BYDUREON™ complete response as a Class 2 resubmission and assigned a new Prescription Drug User Fee Act action date of October 22, 2010.
BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 Thursday, May 6, 2010 @ 7:00AMAmylin Pharmaceuticals, Inc. , Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration has classified the BYDUREONâ¢ complete response as a Class 2 resubmission and assigned a new Prescription Drug User Fee Act action date of October 22, 2010.
Lazy Ox Canteen Brings International Art Food To Downtown Los Angeles Wednesday, May 5, 2010 @ 12:27PMBig Flavor, Small Plates